ArticleFrontiers in immunology2026
Vaccination of newborn monkeys with an influenza HA stem nanoparticle adjuvanted with R848 and AddaVax results in broadened HA recognition and increased antibody secreting cells to HA stem following H1N1 challenge.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: How infection shapes recall responses in the setting of preexisting influenza virus hemagglutinin (HA) stem-focused immunity has important implications given the known impact of imprinting on future immune responses. Adoption of an HA-based universal stem vaccine approach for young infants would likely result in stem-specific imprinting. Understanding how imprinting programs memory B cell recall and early antibody responses to HA stem and head in newborns is therefore essential. Methods: African green monkeys vaccinated with a A/New Caledonia/20/1999 (NC99) hemagglutinin stem-bearing nanoparticle (H1ssF) adjuvanted with R848+AddaVax as newborns were challenged with H1N1 A/California/07/2009 (Ca09). Antibody and draining lymph node cellular responses were analyzed on d7 following challenge. Both quantitative and qualitative aspects of the antibody response were assessed. Results: Our previous studies showed newborn African green monkeys vaccinated with an R848+AddaVax dual adjuvanted H1ssF nanoparticle exhibited a robust stem-specific antibody response that had broad reactivity and enhanced functional activity. In the present study, we investigated how the response elicited by this vaccine was recalled following infection, evaluating both antibody and cellular responses. While challenge resulted in increases in recognition of many heterologous HA molecules, not all responses showed evidence of boosting at this timepoint. Control (Ctrl) animals had limited neutralizing activity to Ca09 at d7 following infection, whereas challenge resulted in significant increases in neutralizing antibody to the challenge virus. Compared to Ctrl animals, vaccinated infants exhibited lower germinal center B cell responses and IFNγ-producing T follicular helper (Tfh) responses. However, vaccinated infants exhibited a significant increase in HA stem-specific plasmablasts and plasma cells in the lung-draining tracheobronchial lymph nodes together with similar head-specific responses. Conclusion: Collectively, these findings are consistent with efficient recall of stem-specific responses generated by vaccination with dual adjuvanted H1ssF administered to newborn African green monkeys in response to influenza virus challenge. Interestingly, challenge with the heterologous virus appears to reshape the reactivity profile of the stem-specific response. Further, vaccinated animals exhibit robust early antibody-secreting cell responses, including increased numbers of stem-specific cells, without an apparent reduction in the generation of head-specific cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.